Cargando…
Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors
BACKGROUND: GSK3368715, a first-in-class, reversible inhibitor of type I protein methyltransferases (PRMTs) demonstrated anticancer activity in preclinical studies. This Phase 1 study (NCT03666988) evaluated safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of GSK3368715 in adults...
Autores principales: | El-Khoueiry, Anthony B., Clarke, James, Neff, Tobias, Crossman, Tim, Ratia, Nirav, Rathi, Chetan, Noto, Paul, Tarkar, Aarti, Garrido-Laguna, Ignacio, Calvo, Emiliano, Rodón, Jordi, Tran, Ben, O’Dwyer, Peter J., Cuker, Adam, Abdul Razak, Albiruni R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338470/ https://www.ncbi.nlm.nih.gov/pubmed/37237172 http://dx.doi.org/10.1038/s41416-023-02276-0 |
Ejemplares similares
-
GSK3- and PRMT-1–dependent modifications of desmoplakin control desmoplakin–cytoskeleton dynamics
por: Albrecht, Lauren V., et al.
Publicado: (2015) -
PRMT1 loss sensitizes cells to PRMT5 inhibition
por: Gao, Guozhen, et al.
Publicado: (2019) -
PRMT5 Promotes Human Lung Cancer Cell Apoptosis via Akt/Gsk3β Signaling
Induced by Resveratrol
por: Li, Yong, et al.
Publicado: (2019) -
PRMT5 regulates colorectal cancer cell growth and EMT via EGFR/Akt/GSK3β signaling cascades
por: Yan, Yongrong, et al.
Publicado: (2021) -
Protein arginine methyltransferases PRMT1, PRMT4/CARM1 and PRMT5 have distinct functions in control of osteoblast differentiation
por: Dashti, Parisa, et al.
Publicado: (2023)